Here’s the latest on RSV vaccines in Australia based on recent reporting and official guidance.
Australia’s first RSV vaccine for adults 60 and over received TGA approval in January 2024. The regulator’s decision marked a milestone as Australia’s initial RSV vaccination option for older adults, with Arexvy from GSK being highlighted as the first RSV vaccine approved in the country. This approval aimed to protect older Australians from RSV-related lower respiratory tract disease, particularly during the winter season.[3]
In parallel, there have been ongoing discussions about expanding RSV vaccination programs, including maternal vaccination for infants and potential inclusion of vaccines in national immunisation programs. Reports from professional bodies in Australia noted plans and advocacy around making RSV vaccines more accessible, including consideration of infant and maternal immunisation strategies.[2][4]
Public and media coverage from early 2024 highlighted access and rollout considerations, with several outlets reporting that RSV vaccines were arriving for the 2024 winter season and that uptake and access could vary by state or territory depending on supply and local policy. Some coverage also called for broader access, including potential public funding or subsidised options.[5][9]
For clinicians and pregnant people, there has been emphasis on risk-based vaccination approaches and ongoing safety data reviews. Professional organisations and health departments in Victoria and other states published guidance and updates on RSV immunisation, vaccines, and safety considerations as the program rolled out.[4][7]
State and national resources through 2024 also provided practical information on vaccine availability, target populations, schedules, and how RSV vaccination fits into broader winter immunisation strategies. Examples include health department pages and professional society updates detailing recommendations and safety profiles for RSV vaccines and monoclonal antibodies.[7][4]
Would you like a concise timeline of key milestones (regulatory approvals, rollout milestones, and major policy discussions) or a quick table comparing the main vaccines mentioned (Arexvy, Abrysvo) and their indicated populations in Australia? I can also pull the latest state-specific rollout status if you specify your preferred state or time window.
Citations:
RSV vaccines are available for Australians for the first time this winter, but depending on what state you live in access may be limited. Linda Baumann battled the virus and knows just how fast it can…
www.abc.net.auThe Therapeutic Goods Administration (TGA) has approved a vaccine against respiratory syncytial virus (RSV) in Australia for the first time. The shot, called Arexvy and manufactured by GSK, will be available by prescription to adults over 60.
www.monash.eduWelcome to South Eastern Melbourne Primary Health Network (SEMPHN). We fund health services across south eastern Melbourne and work with health professionals to improve health outcomes across the catchment.
www.semphn.org.auContagious respiratory disease can create more serious symptoms in people with low immunity
www.theguardian.comAustralia’s first RSV (respiratory syncytial virus) vaccine AREXVY approved by TGA.
au.gsk.comA summary of safety data on respiratory syncytial virus prevention products approved in Australia by the Therapeutic Goods Administration.
www1.racgp.org.auTo ensure ‘every single infant in Australia is protected’, a $174.5 million investment will see free vaccines for pregnant people available nationwide.
www1.racgp.org.auUp to date recommendations, vaccine schedules and resources on RSV (Respiratory syncytial virus) for immunisation providers.
www.health.vic.gov.au